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In Europe, the 2007–08 winter season was dominated 
by infl uenza virus A (H1N1) circulation through week 7, fol-
lowed by infl uenza B virus from week 8 onward. Oseltami-
vir-resistant infl uenza viruses A (H1N1) (ORVs) with H275Y 
mutation in the neuraminidase emerged independently of 
drug use. By country, the proportion of ORVs ranged from 
0% to 68%, with the highest proportion in Norway. The aver-
age weighted prevalence of ORVs across Europe increased 
gradually over time, from near 0 in week 40 of 2007 to 56% 
in week 19 of 2008 (mean 20%). Neuraminidase genes of 
ORVs possessing the H275Y substitution formed a homoge-
neous subgroup closely related to, but distinguishable from, 
those of oseltamivir-sensitive infl uenza viruses A (H1N1). 
Minor variants of ORVs emerged independently, indicating 
multiclonal ORVs. Overall, the clinical effect of ORVs in Eu-
rope, measured by infl uenza-like illness or acute respira-
tory infection, was unremarkable and consistent with normal 
seasonal activity.
Infection with infl uenza viruses A (H1N1), A (H3N2), or B causes substantial human illness and excess deaths 
each year (1,2). Vaccination against seasonal infl uenza is 
the key control measure used in Europe to minimize illness 
and death. Antigenic mismatch between vaccine compo-
nents and circulating viruses occurs every few years, re-
quiring reformulation of the vaccine (1). In addition, sub-
optimal immunization in patient groups for which vaccine 
is recommended provides the rationale for use of antiviral 
drugs in the prophylaxis and treatment of infl uenza. M2 ion 
channel inhibitors (M2Is), amantadine and rimantadine, 
have been available since 1964, but adverse effects, rapid 
development of resistance, and lack of activity against in-
fl uenza B have limited their usefulness (3). The introduc-
tion of neuraminidase inhibitors (NAIs), oral oseltamivir 
and inhaled zanamivir, which are active against both in-
fl uenza type A and B viruses, was a major breakthrough 
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in treatment and prophylaxis of infl uenza using antiviral 
drugs (4). However, prescription data indicate that they are 
not widely used in Europe (Figure 1); by contrast, in Japan 
during the 2003–04 season alone, ≈6 million NAI treatment 
courses were prescribed (5).
Before the introduction of NAIs in 1999, and until 
2007, <1% of viruses tested from unselected surveillance 
studies in a number of countries demonstrated natural re-
sistance to NAIs (5–9). Limited development of resistance 
to oseltamivir has been observed in persons treated, with 
little evidence of onward transmission of resistant viruses 
(10), although low-level transmission of resistant variants 
cannot be discounted (11). However, oseltamivir-resistant 
viruses emerged in 18% (9/50) of treated Japanese children 
with infl uenza virus A (H3N2) infection and 16% (7/43) of 
treated Japanese children with infl uenza virus A (H1N1) 
infection, also with no evidence that these viruses transmit-
ted effi ciently (12,13).
In late January 2008, we reported an unexpected high 
level and unexpected spread of oseltamivir-resistant in-
fl uenza viruses A (H1N1) (ORVs) in Europe caused by a 
H275Y (H274Y in N2 numbering) amino acid substitution 
in the neuraminidase (NA) of these viruses (14). Here, we 
analyze the distribution and transmission of ORVs in Eu-
rope during the winter of 2007–08, when infl uenza viruses 
A (H1N1) were the predominant circulating viruses in Eu-
ropean countries (Table).
Methods
Clinical Infl uenza Activity
The European Infl uenza Surveillance Scheme (EISS) 
actively monitored infl uenza activity from week 40 (Oc-
tober 1–7) of 2007 through week 19 (May 5–11) of 2008. 
EISS covers all 27 European Union countries plus Croa-
tia, Norway, Serbia, Switzerland, Turkey, and Ukraine. In 
each country each week, 1 or several networks of sentinel 
general practitioners (GPs) reported rates of consultation 
for infl uenza-like illness (ILI) or acute respiratory infec-
tion (ARI) (15–17). ARI includes ILI and all other acute 
respiratory infections. For Croatia, Finland, Turkey, and 
Ukraine, no consultation data were available.
Virologic Analysis
Sentinel GPs involved in clinical data recording of 
ILI or ARI also send nasal, pharyngeal, or nasopharyngeal 
specimens from a subset of their patients to the National 
Infl uenza Centers (NICs) for virus detection and character-
ization by using a variety of genetic or phenotypic methods 
(18–20). The NICs also analyzed specimens and infl uenza 
viruses obtained from other sources (e.g., from nonsentinel 
GPs, hospitals, or institutions). For Cyprus and Turkey, no 
virus detection data were available.
Antiviral Drug Susceptibility Monitoring
Antiviral susceptibility data were generated either 
through the European Surveillance Network for Vigilance 
against Viral Resistance (VIRGIL) project at a single labo-
ratory in London (UK Health Protection Agency) or direct-
ly by individual NICs by using methods described previ-
ously (14,21). Genetic analysis of virus isolates or clinical 
specimens was performed by using cycle-sequencing or 
pyrosequencing the NA gene, targeting the H275Y amino 
acid substitution in the N1 NA (22). The 50% inhibitory 
NAI concentration (IC50) of virus isolates was determined 
by using fl uorescent or chemiluminescent enzyme assays 
(23,24). ORVs were defi ned as infl uenza viruses A (H1N1) 
with an IC50 >100 nmol/L for oseltamivir. Susceptibility 
to zanamivir was determined by using the same enzymatic 
method. Susceptibility to M2Is was determined by cycle-
sequencing or pyrosequencing the M2 protein gene, target-
ing known resistance markers. Antiviral susceptibility data 
were not available for Cyprus, Lithuania, and Malta.
Data Analysis
To obtain United Kingdom estimates, clinical and vi-
rologic surveillance data and antiviral susceptibility data 
were totaled for England, Northern Ireland, Scotland, and 
Wales. A single web-based European database at the EISS 
password-protected website (www.eiss.org) was used to 
collect antiviral susceptibility data and linked patient de-
mographic and clinical data (25). Updates on possible re-
sistant viruses were provided at regular intervals to EISS 
members, the World Health Organization, and the Euro-
pean Centre for Disease Prevention and Control.
The timing of the fi rst week of continuous detection of 
infl uenza virus A and ORVs across Europe, both based on 
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Germany 4 211 100 442 128 121 71
France 0 27 49 104 24 93 50
Greece 0 45 41 30 4 2 4
Finland 0 9 2 15 3 7 2
Belgium 1 7 3 33 7 18 8
Austria 0 4 5 30 2 4 7
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Figure 1. Prescription data of oseltamivir treatment courses for 
Western Europe (in thousands); 12 months of data for each year 
2002–2007 and through September for 2008. Data from the United 
Kingdom, the Netherlands, Switzerland, and Portugal are excluded 
because of negligible values. Data provided by IMS Health (www.
imshealth.com), London, UK.
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date of specimen collection, were analyzed by linear regres-
sion analysis using center longitude and center latitude of a 
country as explanatory variables. A maximum interruption 
of 1 week with no infl uenza virus A or ORV detection was 
allowed in estimating the fi rst week of continuous detec-
tion. The average European delay between the fi rst week of 
continuous detection of infl uenza virus A and of ORV was 
calculated as the average of the differences in number of 
weeks between both, by country.
The analysis of temporal trends in the prevalence of 
ORVs in countries and for Europe was confounded by dif-
ferent levels of sampling in different countries (18), en-
hanced antiviral susceptibility testing in some countries, 
and lack of data on the proportion of ORVs for some or 
most weeks for several other countries. To ensure a more 
representative picture of temporal trends in the proportion 
of ORVs, a mixed effect logistic regression modeling ap-
proach (26,27) was used, which allows modeling of bino-
mial proportions, i.e., a numerator and a denominator as a 
function of time, where the coeffi cients of this function are 
allowed to vary for each country around a mean value, com-
bining data from all countries. If there are no observations 
or the denominator is small, the fi t will shrink to its over-
all mean, and uncertainties increase. Three fractions were 
modeled: “ILI per population covered,” “infl uenza A virus 
detections per specimens tested,” and “A (H1N1) resistant 
per A (H1N1) tested.” By multiplying the fi rst 2 fractions 
by the total population, we obtained the number of patients 
with ILI who had infl uenza A in a country. By dividing this 
number by the sum of the number of patients with ILI who 
had infl uenza A for all countries, we obtained the relative 
weights. By multiplying the weights with the prevalences 
of ORVs summed over all countries, we obtained the week-
ly European prevalences of ORVs. The modeled weekly 
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Table. Peak incidence rates of ILI or ARI infection for countries for which data were available, Europe, 2000–01 through 2007–08
influenza seasons* 
Peak incidence rate/10,000 population during influenza season 
2000–01 through 2007–08 
Peak incidence 
rates¶ 
 Dominant virus§ 
Country 
ILI/
ARI† Median Range
Consecutive
no. seasons‡ 2000–01 2007–08
Incidence
rate ratio p value 
Austria# ILI 168.1 108.0–263.2 4 NA 186.1 (H1) 
Belgium ILI 51.9 30.3–95.1 8 30.3 (H1) 38.0 (H1) 1.3 0.004
Bulgaria ARI NA NA 186.0 (H1) 
Czech Republic ARI 188.1 134.5–320.0 8 310.2 (H1) 144.4 (H1) 0.5 1.000
Denmark ILI 30.7 13.8–47.8 8 44.5 (H1) 13.8 (H1) 0.3 1.000
Estonia ILI 2.9 0.6–4.9 3 NA 2.9 (H1) 
France ARI 336.1 279.7–448.8 7 NA 279.7 (H1) 
Germany ARI 185.6 136.9–256.5 8 247.3 (H1) 136.9 (H1/B) 0.6 1.000
Greece ILI 27.7 23.1–42.1 3 NA 23.1 (H1) 
Hungary ILI 50.1 21.0–54.6 3 NA 54.6 (H1) 
Ireland ILI 7.5 2.9–12.1 8 12.1 (H1) 4.9 (H1/B) 0.4 1.000
Italy ILI 79.5 27.6–428.2 8 56.7 (H1) 72.1 (H1/B) 1.3 0.0001
Latvia ILI 45.6 25.1–93.3 5 NA 26.6 (H1) 
Lithuania ILI 34.9 13.3–47.2 7 NA 13.3 (H1) 
Luxembourg ILI 72.6 32.7–79.1 5 NA 67.4 (H1) 
The Netherlands ILI 10.3 6.6–24.0 8 6.9 (H1) 7.2 (H1/B) 1.0 0.400
Norway ILI 18.5 10.9–31.7 3 NA 10.9 (H1/B) 
Poland ILI 23.0 6.2–66.7 7 NA 16.6 (H1) 
Portugal ILI 8.1 3.0–17.4 8 3.8 (H1) 6.2 (H1/B) 1.6 0.016
Romania ILI 1.2 0.4–3.7 4 NA 1.4 (H1) 
Serbia ILI 37.8 30.6–44.9 2 NA 30.6 (H1) 
Slovakia ILI 136.3 49.5–337.3 8 337.3 (H1) 49.5 (H1) 0.1 1.000
Slovenia ILI 15.2 4.5–39.2 8 14.1 (H1) 20.4 (H1) 1.5 0.001
Spain ILI 21.2 4.2–54.1 8 4.2 (H1) 20.3 (H1/B) 4.8 0.0001
Sweden# ILI 2.0 1.6–5.8 5 5.8 (H1) 1.8 (B) 0.3 1.000
Switzerland ILI 39.8 19.4–53.2 7 NA 29.7 (H1) 
United Kingdom ILI 3.8 2.7–8.4 8 5.5 (H1) 2.7 (H1/B) 0.5 1.000
*ILI, influenza-like illness; ARI, acute respiratory infection; NA, data not available. 
†For countries where both ILI and ARI data were available, only the ILI data are shown. 
‡Leading up to 2007–08. 
§Dominant virus estimated on the basis of combined sentinel and nonsentinel data. The limits for codominant virus types/subtypes were 45%:55%. 
¶2007–08 compared with 2000–01. The incidence rate ratio was calculated by dividing the peak incidence rate for 2007–08 by the peak incidence rate for 
2000–01. If the p value estimated using z-statistics is <0.05, the incidence rate ratio is significantly >1, and therefore the peak incidence rate for 2007–08 
is significantly higher than that for 2000–01. 
#Data for seasons 2002–03, 2003–04, and 2004–05 were missing. 
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prevalences of ORVs were subsequently used to calculate 
the average prevalence of ORVs by country and for Europe 
(online Technical Appendix, available from www.cdc.gov/
EID/content/15/4/552-Techapp.pdf).
We performed all statistical analyses by using the soft-
ware package R version 2.8.0 (28). Box-and-whisker plot 
analysis was used to select viruses with outlying high IC50 
values for further analysis (7,29). For oseltamivir outlier 
identifi cation, all viruses defi ned as resistant for oseltami-
vir (IC50 >100 nmol/L) were fi rst removed. Minor outliers 
were defi ned as values lying between the upper quartile 
(UQ) + 1.5 × interquartile region (IQR) and UQ + 3 × IQR; 
major outliers were defi ned as values lying above UQ + 3 × 
IQR, based on analysis of all viruses in a particular subtype 
over a particular winter season.
Phylogenetic analysis of NA and hemagglutinin (HA) 
gene sequences used maximum parsimony (PAUP* version 
4.0; Sinauer Associates, Sunderland, MA, USA). Sequences 
of ORVs and oseltamivir-sensitive infl uenza A (H1N1) vi-
ruses (OSVs) were chosen as representative of infl uenza vi-
ruses A (H1N1) isolated during the 2007–08 infl uenza sea-
son (i.e., weeks 40–52 of 2007 and weeks 1–19 of 2008) in 
different European countries and a few from other regions 
of the world and were compared with those of a few infl u-
enza viruses A (H1N1) isolated before the 2007–08 season, 
including sporadically isolated ORVs. GenBank accession 
numbers are listed in the online Appendix Table (available 
from www.cdc.gov/EID/content/15/4/552-appT.htm).
Results
Seasonal Surveillance
The 2007–08 infl uenza season in Europe was initially 
dominated by infl uenza viruses A (n = 10,720; 60% of all 
infl uenza virus detections). Infl uenza viruses B (n = 7,150; 
40% of all infl uenza virus detections) became dominant in 
week 8 (Figure 2). Of the 5,984 (56%) infl uenza viruses 
A subtyped, 5,748 (96%) were H1, and 236 (4%) were 
H3. Overall, infl uenza virus detections peaked in week 
6, in week 4 for infl uenza viruses A (H1N1), and in week 
8 for infl uenza viruses B. Of the 2,136 infl uenza viruses 
A (H1N1) characterized antigenically, 97% were report-
ed to be closely related to the vaccine strain A/Solomon 
Islands/3/2006, although half of these viruses were report-
ed to be more closely related to A/Brisbane/59/2007, the 
vaccine strain recommended for the 2008–09 season (30).
The fi rst countries in Europe where infl uenza viruses 
A started to circulate continuously were France, Spain, 
Switzerland, and the United Kingdom in week 40. Spatial 
analysis of the timing of the fi rst week of continuous detec-
tion of infl uenza viruses A across Europe (n = 30 coun-
tries) showed a west-to-east pattern: estimated parameter 
for longitude was 0.261 weeks per degree longitude (95% 
confi dence interval [CI] 0.138–0.385, p = 0.001), and for 
latitude –0.108 weeks per degree latitude (95% CI –0.324 
through 0.108, p = 0.366), with R2 = 0.32 for the linear 
regression fi t.
Antiviral Drug Susceptibility
The estimated number of infl uenza viruses A (H1N1) 
among all detected infl uenza viruses A (n = 10,720) was 
10,291 following extrapolation from the proportion of 
96% infl uenza viruses A (H1N1) among all 5,984 sub-
typed infl uenza viruses A. Of the 10,291 infl uenza vi-
ruses A (H1N1), 2,949 (29%) were tested for antiviral 
susceptibility, 1,080 by both phenotypic assay (IC50) and 
sequencing, 601 by phenotypic assay alone, and 1,268 
by sequencing alone. Of the 2,949 viruses tested, 712 
(24%) were oseltamivir resistant either by presence of the 
H275Y substitution (n = 548) or an IC50 >100 nmol/L for 
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Figure 2. Total number of infl uenza virus detections, by type and 
subtype and by week, Europe, winter 2007–08.
Figure 3. Total infl uenza A viruses subtyped as H1N1 and number 
of oseltamivir-resistant or oseltamivir-sensitive viruses among 
the subset of infl uenza viruses A (H1N1) for which oseltamivir 
susceptibility was determined, by week, Europe, winter 2007–08.
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oseltamivir (n = 463) (Figure 3). Correlation was 100% 
between sensitive phenotype (IC50 <100 nmol/L) and the 
presence of H275 (n = 781) and between resistant phe-
notype (IC50 >100 nmol/L) and the presence of Y275 
(n = 299). OSVs (n = 1,218) had a median IC50 of 1.7 
nmol/L for oseltamivir (range 0.1 nmol/L–23.2 nmol/L) 
and only 9 minor outliers (thresholds IC50 >12.0 nmol/L 
and <53.1 nmol/L) were identifi ed. ORVs (n = 463) had 
a median IC50 of 653 nmol/L (range 140 nmol/L–4,000 
nmol/L). None of the 429 phenotypically characterized 
ORVs showed evidence of resistance to zanamivir (me-
dian IC50 1.8 nmol/L, range 0.2 nmol/L–25.8 nmol/L), and 
only 17 minor outliers (thresholds IC50 >8.5 nmol/L and 
<27.5 nmol/L) were identifi ed. None of 237 ORVs tested 
for M2I sensitivity had any of the common resistance sub-
stitutions in the M2 protein.
ORVs were detected in 22 of the 30 countries for which 
susceptibility data were available, with Norway having the 
highest proportion of ORVs (Figure 4). Modeling showed 
the overall average prevalence of ORVs by country ranged 
from 8.3% (95% CI 1.3%–21%) in Italy to 65.0% (95% CI 
58.2%–71.3%) in Norway; for Europe, the average preva-
lence of ORVs was 20.1% (95% CI 15.2%–24.6%).
The earliest detection of ORVs was in France and the 
United Kingdom in week 46 and in Norway in week 47. 
Countries where continuous detection of ORVs fi rst be-
gan included Norway in week 47, France in week 49, the 
United Kingdom in week 51, and the Netherlands in week 
52. Spatial analysis of the timing of the fi rst week of con-
tinuous ORV detection across Europe (n = 14 countries) 
showed a west-to-east trend pattern: estimated parameter 
for longitude was 0.156 weeks per degree longitude (95% 
CI 0.033–0.280, p = 0.031), and for latitude 0.007 weeks 
per degree latitude (95% CI –0.209 through 0.223, p = 
0.953), with R2 = 0.36 for the linear regression fi t. The av-
erage delay between the fi rst week of continuous detection 
of infl uenza virus A and continuous detection of ORV was 
5.7 weeks (range 0–15, 95% CI 2.8–8.4).
Modeling showed a gradual increase for Europe in 
prevalence of ORVs over time, from close to 0 in week 40 
to ≈56% in week 19 (Figure 5). This overall increase re-
fl ected prevalence increases in most individual countries in 
addition to Norway where the modeled prevalence started 
high at ≈60% and remained so throughout the period of 
virus circulation (online Appendix Figure, available from 
www.cdc.gov/EID/content/15/4/552-appF.htm). Outside 
the main infl uenza virus A (H1N1) outbreak period, from 
week 51 to week 10 (Figure 2), the CIs for the prevalence 
of ORVs by country and for Europe were wide (Figure 5; 
online Appendix Figure) because of the low numbers of 
infl uenza virus A (H1N1) detected or analyzed for antiviral 
resistance (online Technical Appendix).
Phylogenetic Analysis
Phylogenetic comparisons of HA and NA genes 
showed that the sequences of most recent European infl u-
enza viruses A (H1N1) fell within clade 2B, represented by 
A/Brisbane/59/2007, the recently recommended vaccine 
virus for 2008–09 (Figure 6). The NA sequences of most 
European ORVs form a cluster, characterized by a differ-
ence in amino acid residue 354 (D354G), as well as 275 
(H275Y) compared with OSVs, including some ORVs from 
the United States and Japan (30,31). A degree of heteroge-
neity was observed, especially among ORVs from the Unit-
ed Kingdom; however, the NA sequences in these smaller 
clusters, represented by, for example, A/Scotland/5/2008 
(and A/Hawaii/21/2007) or A/England/654/2007, are not 
distinguished from those of OSVs by any common amino 
acid differences other than H275Y. Some of these sequenc-
es fall close to those of ORVs recently isolated in Japan 
(31). The corresponding HA gene sequences within clade 
2B, however, did not exhibit segregation complementary 
to that for NA gene sequences and no common amino 
acid changes distinguished ORVs and OSVs (Figure 6). 
Although the D344N substitution in NA has been associ-
ated with increases in the enzyme activity (32), this amino 
acid is common to both clades 2B and 2C, and none of the 
clade-specifi c differences between the NA (13 amino acids) 
or HA (6 amino acids) can readily account for the greater 
proportion of ORVs in clade 2B over clade 2C viruses.
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Figure 4. Modeled average prevalence of oseltamivir-resistant 
infl uenza viruses A (H1N1), with 95% confi dence intervals (error 
bars), ranked by country, Europe, winter 2007–08. Text columns on 
the right list the absolute cumulative number of oseltamivir-resistant 
infl uenza viruses A (H1N1) and number of infl uenza viruses A 
(H1N1) tested for oseltamivir susceptibility per country.
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Discussion
Unexpectedly, infl uenza viruses A (H1N1) with a sin-
gle amino acid substitution H275Y in the NA, which caused 
a several hundred-fold selective reduction in susceptibility 
to oseltamivir, emerged and were sustained in circulation 
in Europe during 2007–08, despite low antivirual drug use 
(Figure 1). Before the 2007–08 season, <1% of viruses 
tested since the start of European antiviral surveillance 
in 2004 had IC50 values >100 nmol/L for NAI drugs (A. 
Lackenby et al., unpub. data), in concordance with results 
from worldwide surveillance (8,9). In 2007–08, infl uenza 
viruses A (H3N2) and B circulating in Europe remained 
sensitive to NAI drugs.
This emergence of oseltamivir-resistant infl uenza vi-
rus A (H1N1) in Europe coincided with the dominant cir-
culation of this virus subtype during the 2007–08 winter 
in Europe and the emergence of a new drift variant, A/
Brisbane/59/2007 (30). Of the last 12 infl uenza seasons, in-
fl uenza viruses A (H1N1) were dominant only in 2000–01, 
which included a new drift variant, A/New Caledonia/20/99 
(20). In the other 10 seasons, infl uenza viruses A (H1N1) 
played a minor role, with infl uenza viruses A (H3N2) domi-
nant in 9 seasons. Compared with 2000–01, peak incidence 
rates for ILI or ARI in 7 of 13 countries were similar or 
lower in 2007–08 (Table). In 6 countries, the peak inci-
dence rates were signifi cantly higher in 2007–08 than in 
2000–01, but with a <2-fold difference in 5 countries and, 
in Spain only, a 4.8-fold difference. Both the 2000–01 and 
2007–08 seasons were unremarkable in the overall clinical 
impact of infl uenza, with normal seasonal activity as mea-
sured by comparison of peak incidence rates for all seasons 
since 2000–01.
Sporadically occurring A/New Caledonia/20/99-like 
ORVs with H275Y were detected during the 2006–07 sea-
son in the United Kingdom and United States but did not 
become epidemiologically important. Indeed, the genetic 
background plays a role in retaining the replication effi -
ciency and pathogenicity of recombinant infl uenza viruses 
A (H5N1) and A (H1N1) after introduction of tyrosine at 
position 275 (33). Furthermore, other previously analyzed 
infl uenza viruses A (H1N1) with the H275Y mutation 
showed impaired replicative ability in cell culture and re-
duced infectivity and substantially compromised pathoge-
nicity in animal models, compared with the corresponding 
wild-type virus (34,35). The coincidental emergence of 
H275Y with the circulation of the A/Brisbane/59/2007 drift 
variant may have favored the emergence of fi t transmissible 
ORVs. This point is also illustrated by the emergence of A/
Brisbane/59/2007-like ORVs in other parts of the Northern 
Hemisphere and their continued circulation during the 2008 
Southern Hemisphere infl uenza epidemic season (36–38). 
Since the last quarter of 2007, ORVs have been detected 
in continents other than Europe, with proportions of ORVs 
varying from 100% in South Africa and Australia to <5% 
in Japan. Trend data are limited: a slight monthly increase 
was noted in China/Hong Kong and Japan; in Canada, the 
increase was similar to that in Europe, from 0% ORVs in 
November 2007 to 86% ORVs in April 2008 (36).
Using modeling, we showed that the prevalence of 
ORVs increased in the European region from ≈0% at the 
start to 56% at the end of the season. The fi nding of a high 
prevalence of ORVs in the community and the overall tem-
poral increase in resistance demonstrates that the previously 
documented reduced fi tness of viruses bearing the H275Y 
mutation, ostensibly caused by structural and functional 
constraints (10), has been overcome in currently circulating 
infl uenza viruses A (H1N1). The results of Rameix-Welti 
et al. (32) suggest that a combination of specifi c amino acid 
substitutions have increased the affi nity of the NA of recent 
infl uenza viruses A (H1N1) (ORVs and OSVs) for sub-
strate. A better balance of NA and HA activities in ORVs 
compared with OSVs may have contributed to the over-
all fi tness and transmissibility of ORVs. However, growth 
curves conducted in tissue culture of pairs of ORVs and 
OSVs demonstrated no differences in growth kinetics or fi -
nal virus yields. Therefore, changes in other genes also may 
be involved in the overall impact on the fi tness of ORVs, 
for which whole genome sequencing is necessary.
For Europe, no focal point of initiation of spread could 
be identifi ed. The spread of ORV from west to east paral-
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Figure 5. Weighted average prevalence of oseltamvir-resistant 
infl uenza viruses A (H1N1), Europe, winter 2007–08. The light gray 
region indicates the 95% confi dence interval.
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leled that of infl uenza virus A in Europe, and there was an 
average delay of 5.7 weeks for the appearance of ORVs 
after the start of infl uenza virus A circulation. However, the 
low R2 values for both patterns make defi nitive conclusions 
diffi cult to draw about the spatial spread of either infl uen-
za viruses A or ORVs. Several independent introductions 
into European countries of a sensitive and a resistant strain 
might explain the low R2 values.
Estimating whether a global focal point exists from 
which ORVs emerged to spread to the rest of the world is 
not possible, but the fact that Japan, the country with the 
highest per capita use of oseltamivir (5), had relatively low 
levels of circulating ORVs during the 2007–08 infl uenza 
season is relevant and refl ects the limited circulation of the 
clade 2B A/Brisbane/59/2007-like viruses belonging to the 
European cluster in this region (31,36).
The close relationships between the NA sequences 
of most of the 2007–08 European ORVs and their segre-
gation from those of OSVs suggest that resistance results 
in large part from the spread of a single variant. Phyloge-
netic analyses show that this is a property of clade 2B A/
Brisbane/59/2007-like viruses and is not associated with 
emergence of another antigenic variant. However, identi-
fi cation of other resistant variants in the United Kingdom, 
some of which are more closely related to OSVs than to 
most ORVs (e.g., A/England/654/2007) indicates the inde-
pendent parallel emergence of multiple resistant variants. 
This is emphasized by small distinct clusters of closely re-
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Figure 6. Phylogenetic comparisons of the hemagglutinin (A) and neuraminidase (B) genes of infl uenza viruses A (H1N1). Sequences 
of oseltamivir-resistant viruses, possessing the H275Y (H274Y in N2 numbering) mutation are in boldface; vaccine strains are in italics. 
Common amino acid changes that distinguish clades 1 and 2 and subgroups of clade 2 are shown. Scale bars indicate 0.01 nucleotide 
substitutions per site.
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lated ORVs in Japan that are related to European OSVs, 
whereas only a few of the Japanese ORVs belonged to the 
large European ORVs cluster (31). Resolution of the origin 
and frequency of emergence of ORVs and association with 
drug use clearly require substantially more intimate knowl-
edge of the genetic relationships among OSVs and ORVs 
worldwide. Our observations suggest that the new genetic 
background of infl uenza viruses A (H1N1) that appeared 
in 2007 enabled the virus to develop oseltamivir resistance 
independently at several locations in the world.
The combined effect of the relatively high level of cir-
culation of infl uenza viruses A (H1N1) in Europe; the in-
troduction of a new antigenic drift variant in a susceptible 
population, partly related to the lack of substantial infl u-
enza virus A (H1N1) circulation since the 2000–01 season; 
and the uncompromised transmissibility of the ORVs con-
tributed to the epidemiologic success of the ORVs during 
the 2007–08 season. This phenomenon shows clearly that 
continuation of antiviral susceptibility monitoring and in-
creasing capacity for timely response are essential (21,39). 
In addition, the appearance of viable transmitting ORVs is 
a reminder that the level of resistance to oseltamivir of sea-
sonal or pandemic virus cannot be predicted, and therefore 
antiviral strategies should not rely on single drugs (40). Al-
though oseltamivir remains a valuable infl uenza antiviral 
agent, the emergence of natural resistance shifts attention 
from oseltamivir to other antiviral agents and to improved 
vaccination (e.g., greater vaccination coverage, more im-
munogenic and broadly reacting vaccines) in the fi ght 
against seasonal and pandemic infl uenza.
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